What is Ionis Pharmaceuticals, Inc.'s Shariah compliance score?

Ionis Pharmaceuticals, Inc.'s (IONS) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does Ionis Pharmaceuticals, Inc. pass AAOIFI screening?

Ionis Pharmaceuticals, Inc. (IONS) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (IONS: 20.2%), (3) interest-bearing deposits below 30% (IONS: 29.8%), and (4) prohibited income below 5% (IONS: 18.6%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for Ionis Pharmaceuticals, Inc. stock?

Ionis Pharmaceuticals, Inc. (IONS) has a non-permissible income ratio of 18.57%. Muslim investors should purify this percentage of any dividends received and capital gains realized from IONS shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen Ionis Pharmaceuticals, Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Ionis Pharmaceuticals, Inc. (IONS) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about IONS's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

IONS: Is Ionis Pharmaceuticals, Inc. Halal?

Ionis Pharmaceuticals, Inc.

NASDAQHealthcareUS

$81.80

+3.30%

Market Cap: 13.5B

Compliance Status

Not Halal

Screened on Jul 18, 2026 · AAOIFI Standard 21

Non-Compliant

0Score

Is Ionis Pharmaceuticals, Inc. (IONS) halal? Not Halal. Based on AAOIFI screening, Ionis Pharmaceuticals, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Within the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

20.2% of 30.0% limit

What this means for you

Most scholars advise not holding IONS

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Ionis Pharmaceuticals, Inc.

Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jul 18, 2026

Compliance History

Not Halalnow
since Jun 2026
Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.45

-0.02%

0002.KLA+

Kotra Industries Bhd

$3.72

+0.01%

0075.KLA+

LYC Healthcare Bhd

$0.01

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.47

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.29

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track IONS and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Ionis Pharmaceuticals, Inc. (IONS) halal to invest in?

Ionis Pharmaceuticals, Inc. (IONS) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did Ionis Pharmaceuticals, Inc. get a F compliance rating?

Ionis Pharmaceuticals, Inc. (IONS) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 20.2% (limit 30%); interest-bearing deposits of 29.8% (limit 30%); prohibited income of 18.57% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Ionis Pharmaceuticals, Inc.'s Shariah verdict?

Ionis Pharmaceuticals, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Ionis Pharmaceuticals, Inc. re-screened for Shariah compliance?

Ionis Pharmaceuticals, Inc. (IONS) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jul 18, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.